Phacilitate

  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Back
  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Join Today
Sign In
Sign In
Join Today

Workshop: A Design Team’s Views on Optimizing your Viral Vector for Clinical Success

Banner
Phacilitate
20 July 2023
SHARE NOW
Cell Therapy
Gene Therapy
Strategy
Viral/Non-Viral Vectors

APPLICATIONS ARE NOW CLOSED | MEET THE PANEL
Thursday, August 24, 2023 | 11:00 [EDT] | 08:00 [PDT] | 16:00 [BST]

A VIRTUAL PARTICIPATORY WORKSHOP

Vector design and optimization is often a stumbling block for translational and clinical success.

Don’t miss this opportunity to get specific answers to your challenging questions from Dr Farzin Farzaneh, a global expert with decades of expertise and success in lentiviral and gammaretro vector design, development, and optimization. Farzin and his team have created a proprietary platform that incorporates intelligent design, helping to develop the best vector and de-risk your clinical candidate.

What would you ask Farzin and his team if you had the chance?

Audience participation is paramount at this workshop and spaces are limited. To allow us to cover as many of your questions and case studies as possible, please register your interest and provide as much detail as possible through the form below. The Phacilitate team will be in touch to let you know if your registration for this session has been successful.

Please note that the closing date for submitting questions and case studies is Monday, August 21.

Apply to join the session, here >> 

Inspiration for questions:

  • Factors that impact design requirements, e.g., tumor type
  • Quality considerations and packaging plasmids
  • Overcoming titer challenges

Join us at this virtual workshop – in collaboration with the team at ViroCell Biologics – to discuss the design, development and optimization of lentiviral vectors and accelerate your pathway to the clinic.

Joining Farzin from the ViroCell Biologics team will be John Hadden, CEO & Co-Founder, Carlo Scala, Director, Process Development & Innovation and Glenda Dickson, Principal Scientist, Innovation.

MEET THE PANEL

John W. Hadden II
Chief Executive Officer & Co-Founder
ViroCell Biologics

 

Farzin Farzaneh, PhD, FRCPath, FRSB
Chief Scientific Officer & Co-Founder, ViroCell Biologics
Professor of Molecular Medicine, King’s College London

 

Carlo Scala, PhD
Director, Process Development & Innovation
ViroCell Biologics

 

Glenda Dickson PhD, MMedSc, BSc (Hons)
Principal Scientist, Innovation
ViroCell Biologics

Apply to join the session, here >>

This webinar is brought to you in partnership with ViroCell Biologics.

 

More like this

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Taysha is discontinuing the development of TSHA-120 in GAN following the Type C meeting feedback from the FDA
21 September 2023

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

Oxford Biomedica in Exclusive Talks to Acquire ABL Europe from Institut Mérieux.
20 September 2023

The Cell & Gene Therapy Manufacturing Capacity Map

The only live, interactive manufacturing capacity compendium for the advanced therapies industry.
20 September 2023

Discover more like this

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

The Cell & Gene Therapy Manufacturing Capacity Map

Broken String Bioscience Closes $15M Series A Funding Round

FDA Delays the Review of Iovance’s BLA Treatment of Advanced Melanoma

logo_footer
logo_mobile_footer
Company
  • About Us
  • Events
  • Contact Us
Resources
  • Insights and Resources
  • Latest News
  • Phacilitate Podcast
  • Content Services
Network
  • Sign In
  • Join Today
social_icon Linkedin
social_icon Twitter

Clarion Events Limited is registered in England and Wales, Company Number 00454826, VAT No. GB 843845601 Registered Office: Bedford House, 69-79 Fulham High Street, London, SW6 3JW, United Kingdom.

  • Privacy Policy
  • Code of Conduct
  • Terms & Conditions
  • Cookies
Phacilitate is a part of Clarion Events Limited. © Phacilitate 2022